Aggiornamento
Osteoporosi nel bambino e nell'adolescente
OSTEOPOROSIS IN CHILDREN AND ADOLESCENTS
GIAMPIERO IGLI BARONCELLI, SILVANO BERTELLONI, FRANCESCO VIERUCCI
UO di Pediatria II, Azienda Ospedaliero - Universitaria Pisana, Ospedale “S. Chiara”, Pisa
Novembre 2008 - pagg. 563 -569
Abstract
Osteoporosis may affect children and adolescents with various disorders. Diagnosis is based on an accurate history and clinical examination in addition to radiologic and densitometric evaluation. Densitometric techniques have a key role in the diagnosis and followup of patients with osteoporosis giving a quantitative analysis of bone mineral status. Dual energy X-ray absorptiometry (DXA) and quantitative ultrasound (QUS) are the main
densitometric techniques used in children and adolescents. Bisphosphonates are the more efficacious treatment for patients with osteoporosis but our experience remains limited to few patients and osteoporotic disorders. Therefore, bisphosphonate treatment should be performed in selected patients after informed consent by parents.
Classificazione MeSH
Bibliografia
1. Matkovic V, Jelic T, Wardlaw GM, et al. Timing
of peak bone mass in caucasian females
and its implication for the prevention of osteoporosis.
Inference from a cross-sectional model.
J Clin Invest 1994;93:799-808.
2. NIH Consensus Development Program. Osteoporosis prevention, diagnosis and therapy. NIH Consensus Statements 2000;17:1- 45.[http://consensus.nih.gov/cons/111/ 111_intro.htm].
3. Lewiecki EM, Gordon CM, Baim S, et al. Special Report on the 2007 Adult and Pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int 2008;19:1369-78.
4. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Osteoporosis in children and adolescents: etiology and management. Paediatr Drugs 2005;7:295-323.
5. Antoniazzi F, Baroncelli GI, Bertelloni S, et al. Metodiche di valutazione della densitŕ minerale ossea nel bambino e nell’adolescente. Riv Ital Med Adol 2006;4:25-9.
6. Baroncelli GI. Quantitative ultrasound methods to assess bone mineral status in children: technical characteristics, performance, and clinical application. Pediatr Res 2008;63: 220-8.
7. Baroncelli GI, Federico G, Vignolo M, et al. Cross-sectional reference data for phalangeal quantitative ultrasound from early childhood to young-adulthood according to gender, age, skeletal growth, and pubertal development. Bone 2006;39:159-73.
8. Koné Paut I, Gennari JM, Retornaz K, Jouve JL, Bollini G. Les biphosphonates chez l’enfant: présent et avenir. Arch Pédiatr 2002; 9:836-42.
9. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M. Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Pediatr Child Health 2003;39:88-92.
10. Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007;4:CD005324.
11. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119 (Suppl 2):S150-62.
2. NIH Consensus Development Program. Osteoporosis prevention, diagnosis and therapy. NIH Consensus Statements 2000;17:1- 45.[http://consensus.nih.gov/cons/111/ 111_intro.htm].
3. Lewiecki EM, Gordon CM, Baim S, et al. Special Report on the 2007 Adult and Pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int 2008;19:1369-78.
4. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Osteoporosis in children and adolescents: etiology and management. Paediatr Drugs 2005;7:295-323.
5. Antoniazzi F, Baroncelli GI, Bertelloni S, et al. Metodiche di valutazione della densitŕ minerale ossea nel bambino e nell’adolescente. Riv Ital Med Adol 2006;4:25-9.
6. Baroncelli GI. Quantitative ultrasound methods to assess bone mineral status in children: technical characteristics, performance, and clinical application. Pediatr Res 2008;63: 220-8.
7. Baroncelli GI, Federico G, Vignolo M, et al. Cross-sectional reference data for phalangeal quantitative ultrasound from early childhood to young-adulthood according to gender, age, skeletal growth, and pubertal development. Bone 2006;39:159-73.
8. Koné Paut I, Gennari JM, Retornaz K, Jouve JL, Bollini G. Les biphosphonates chez l’enfant: présent et avenir. Arch Pédiatr 2002; 9:836-42.
9. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M. Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Pediatr Child Health 2003;39:88-92.
10. Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007;4:CD005324.
11. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119 (Suppl 2):S150-62.
Corrispondenza: g.baroncelli@med.unipi.it